Free Trial
OTCMKTS:CZMWY

Carl Zeiss Meditec (CZMWY) Stock Price, News & Analysis

Carl Zeiss Meditec logo
$49.68 +1.94 (+4.06%)
As of 01/17/2025 03:51 PM Eastern

About Carl Zeiss Meditec Stock (OTCMKTS:CZMWY)

Key Stats

Today's Range
$48.99
$49.69
50-Day Range
$46.38
$64.49
52-Week Range
$46.13
$134.60
Volume
13,723 shs
Average Volume
14,675 shs
Market Capitalization
N/A
P/E Ratio
54.00
Dividend Yield
0.60%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

Carl Zeiss Meditec Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
12th Percentile Overall Score

CZMWY MarketRank™: 

Carl Zeiss Meditec scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Carl Zeiss Meditec.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Carl Zeiss Meditec is 54.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.80.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Carl Zeiss Meditec is 54.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.34.

  • Read more about Carl Zeiss Meditec's valuation and earnings.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Carl Zeiss Meditec has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Carl Zeiss Meditec has recently increased by 766.67%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Carl Zeiss Meditec pays a meaningful dividend of 1.36%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Carl Zeiss Meditec does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Carl Zeiss Meditec is 32.64%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Carl Zeiss Meditec's dividend.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Carl Zeiss Meditec has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Carl Zeiss Meditec has recently increased by 766.67%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Carl Zeiss Meditec has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.
Receive CZMWY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carl Zeiss Meditec and its competitors with MarketBeat's FREE daily newsletter.

CZMWY Stock News Headlines

Kepler Capital Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)
Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
RBC Capital Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)
Carl Zeiss: Why I Am So Positive
See More Headlines

CZMWY Stock Analysis - Frequently Asked Questions

Carl Zeiss Meditec's stock was trading at $47.50 at the beginning of the year. Since then, CZMWY stock has increased by 4.6% and is now trading at $49.68.
View the best growth stocks for 2025 here
.

Shares of CZMWY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
1/20/2025
Next Earnings (Estimated)
2/12/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Instruments & Supplies
Sub-Industry
N/A
Current Symbol
OTCMKTS:CZMWY
CIK
N/A
Fax
N/A
Employees
4,823
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (OTCMKTS:CZMWY) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners